These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24057325)

  • 1. Prognostic value of Musashi-1 in gliomas.
    Dahlrot RH; Hansen S; Herrstedt J; Schrøder HD; Hjelmborg J; Kristensen BW
    J Neurooncol; 2013 Dec; 115(3):453-61. PubMed ID: 24057325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival.
    Strojnik T; Røsland GV; Sakariassen PO; Kavalar R; Lah T
    Surg Neurol; 2007 Aug; 68(2):133-43; discussion 143-4. PubMed ID: 17537489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the clinical value of cancer stem cell markers in gliomas?
    Dahlrot RH; Hermansen SK; Hansen S; Kristensen BW
    Int J Clin Exp Pathol; 2013; 6(3):334-48. PubMed ID: 23412423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and prognostic value of the WEE1 kinase in gliomas.
    Music D; Dahlrot RH; Hermansen SK; Hjelmborg J; de Stricker K; Hansen S; Kristensen BW
    J Neurooncol; 2016 Apr; 127(2):381-9. PubMed ID: 26738845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of CD133 and nestin in patients with glioma: a population-based study.
    Dahlrot RH; Hansen S; Jensen SS; Schrøder HD; Hjelmborg J; Kristensen BW
    Int J Clin Exp Pathol; 2014; 7(7):3739-51. PubMed ID: 25120750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and prognostic value of JAM-A in gliomas.
    Rosager AM; Sørensen MD; Dahlrot RH; Boldt HB; Hansen S; Lathia JD; Kristensen BW
    J Neurooncol; 2017 Oct; 135(1):107-117. PubMed ID: 28677106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DDX3X Biomarker Correlates with Poor Survival in Human Gliomas.
    Hueng DY; Tsai WC; Chiou HY; Feng SW; Lin C; Li YF; Huang LC; Lin MH
    Int J Mol Sci; 2015 Jul; 16(7):15578-91. PubMed ID: 26184164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF2 as a potential prognostic biomarker for proneural glioma patients.
    Sooman L; Freyhult E; Jaiswal A; Navani S; Edqvist PH; Pontén F; Tchougounova E; Smits A; Elsir T; Gullbo J; Lennartsson J; Bergqvist M; Ekman S
    Acta Oncol; 2015 Mar; 54(3):385-94. PubMed ID: 25263081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.
    Thon N; Damianoff K; Hegermann J; Grau S; Krebs B; Schnell O; Tonn JC; Goldbrunner R
    Mol Cell Neurosci; 2010 Jan; 43(1):51-9. PubMed ID: 18761091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients.
    Yang X; Li D; Cheng S; Fan K; Sheng L; Zhang J; Feng B; Xu Z
    Tumour Biol; 2014 Nov; 35(11):11091-5. PubMed ID: 25099618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slit2 and Robo1 expression as biomarkers for assessing prognosis in brain glioma patients.
    Liu L; Li W; Geng S; Fang Y; Sun Z; Hu H; Liang Z; Yan Z
    Surg Oncol; 2016 Dec; 25(4):405-410. PubMed ID: 27916173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of stem cell markers in proliferating cells in glioma.
    Rehfeld M; Matschke J; Hagel C; Willenborg K; Glatzel M; Bernreuther C
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):2969-2982. PubMed ID: 34170383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional expression of ZICs as an independent indicator of survival in gliomas.
    Han Z; Jia J; Lv Y; Wang R; Cao K
    Sci Rep; 2021 Sep; 11(1):17532. PubMed ID: 34475426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of Musashi-1 in endometrioid adenocarcinoma.
    Ma L; Xu YL; Ding WJ; Shao HF; Teng YC
    Int J Clin Exp Pathol; 2015; 8(5):4564-72. PubMed ID: 26191146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental validation of 5 in-silico predicted glioma biomarkers.
    Towner RA; Jensen RL; Vaillant B; Colman H; Saunders D; Giles CB; Wren JD
    Neuro Oncol; 2013 Dec; 15(12):1625-34. PubMed ID: 24158112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays.
    He J; Liu Y; Zhu T; Zhu J; Dimeco F; Vescovi AL; Heth JA; Muraszko KM; Fan X; Lubman DM
    Mol Cell Proteomics; 2012 Jun; 11(6):M111.010744. PubMed ID: 22203689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-Regulation of Long Non-Coding RNA AB073614 Predicts a Poor Prognosis in Patients with Glioma.
    Hu L; Lv QL; Chen SH; Sun B; Qu Q; Cheng L; Guo Y; Zhou HH; Fan L
    Int J Environ Res Public Health; 2016 Apr; 13(4):433. PubMed ID: 27104549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone H1.0--a potential molecular marker with prognostic value for patients with malignant gliomas.
    Gabrovsky N; Georgieva M; Laleva M; Uzunov K; Miloshev G
    Acta Neurochir (Wien); 2013 Aug; 155(8):1437-42. PubMed ID: 23812966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
    Wu X; Wu F; Xu D; Zhang T
    J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.